|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Corbus Pharmaceuticals Holdings, Inc.
| | | Phone: | (617) 963-0100 | Year Established: | 2009 | Ticker: | CRBP | Exchange: | NASDAQ | Main Contact: | Yuval Cohen, Ph.D., CEO | | Other Contacts: | Robert Discordia, Ph.D., Pharmaceutical Development & Manufacturing Ross Lobell, VP, Regulatory Affairs Sean Moran, CPA, CFO Barbara White, M.D., CMO Mark A. Tepper, Ph.D., President & CSO
| | Company Description | Corbus Pharmaceuticals is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Our lead product candidate Resunab™ is a novel oral drug that resolves chronic inflammation and fibrotic processes. Resunab is scheduled to commence Phase 2 clinical trials for the treatment of cystic fibrosis, diffuse cutaneous systemic sclerosis ("scleroderma"), and skin-predominant dermatomyositis in 2015. | |
|
|
|
|
|